Cargando…

Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm

5α-dihydrotestosterone (5α-DHT) is the most potent natural androgen. 5α-DHT elicits a multitude of physiological actions, in a host of tissues, including prostate, seminal vesicles, hair follicles, skin, kidney, and lacrimal and meibomian glands. However, the physiological role of 5α-DHT in human ph...

Descripción completa

Detalles Bibliográficos
Autor principal:	Traish, Abdulmaged M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Sexual Medicine and Andrology 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308241/ https://www.ncbi.nlm.nih.gov/pubmed/32202088 http://dx.doi.org/10.5534/wjmh.200012

Ejemplares similares

Bone Health Risks Associated with Finasteride and Dutasteride Long-Term Use
por: Sirufo, Maria Maddalena, et al.
Publicado: (2021)

Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2013)

A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride
por: Antoniou, Tony, et al.
Publicado: (2018)

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride
por: Choi, Yong Hyeuk, et al.
Publicado: (2010)

Does treatment with dutasteride or finasteride has impact on renal morphology? Experimental study
por: da Silva, Marcello Henrique Araújo, et al.
Publicado: (2021)

Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
por: Kiguradze, Tina, et al.
Publicado: (2017)

The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
por: Laanani, Moussa, et al.
Publicado: (2023)

Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
por: Choi, Gwang-Seong, et al.
Publicado: (2022)

The Effect of Finasteride and Dutasteride on the Growth of WPE1-NA22 Prostate Cancer Xenografts in Nude Mice
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2012)

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis
por: Li, Yao, et al.
Publicado: (2022)

Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2016)

The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model
por: Da Silva, Marcello H A, et al.
Publicado: (2018)

Sounding the Alarm: Health in the Anthropocene
por: Butler, Colin D.
Publicado: (2016)

Commentary Regarding the Effect of Long Term Use of Finasteride on Saudi Women
por: Al-Qahtani, Wedad Saeed, et al.
Publicado: (2020)

Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials
por: Zhou, Zhongbao, et al.
Publicado: (2020)

Erratum: Correction of the references for Figures. Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2017)

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States
por: DerSarkissian, Maral, et al.
Publicado: (2016)

Androgens Modulate Endothelial Function and Endothelial Progenitor Cells in Erectile Physiology
por: Traish, Abdulmaged M., et al.
Publicado: (2013)

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome
por: Traish, Abdulmaged M., et al.
Publicado: (2018)

Testosterone and weight loss: the evidence
por: Traish, Abdulmaged M.
Publicado: (2014)

Sex steroids and COVID-19 mortality in women
por: Traish, Abdulmaged M.
Publicado: (2021)

Sound the Alarm: Fraud in Neuroscience
por: Lisberger, Stephen G.
Publicado: (2013)

Failure to Replicate: Sound the Alarm
por: Ioannidis, John P.A.
Publicado: (2015)

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

Obesity and Erectile Dysfunction: Is Androgen Deficiency the Common Link?
por: Feeley, Robert J., et al.
Publicado: (2009)

Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups
por: Traish, Abdulmaged M., et al.
Publicado: (2017)

The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2017)

Life in the flame: Inflammation sounds the alarm for suicide risk
por: Yan, Wen-Jie, et al.
Publicado: (2021)

The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
por: Traish, Abdulmaged M., et al.
Publicado: (2014)

Update on the use of dutasteride in the management of benign prostatic hypertrophy
por: Miller, Joe, et al.
Publicado: (2007)

Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors – dutasteride and finasteride – in the presence of testosterone
por: Hatanaka, Toshiki, et al.
Publicado: (2021)

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Saad, Farid, et al.
Publicado: (2019)

Early origins sound S phase alarm
por: LeBrasseur, Nicole
Publicado: (2008)

Editors sound the SARS alarm bells
por: Dixon, Bernard
Publicado: (2003)

OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fhvv9374g7i5qtjrtt1u2beots